<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898065</url>
  </required_header>
  <id_info>
    <org_study_id>RC11-080</org_study_id>
    <secondary_id>2011-004582-32</secondary_id>
    <nct_id>NCT01898065</nct_id>
  </id_info>
  <brief_title>Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer</brief_title>
  <acronym>HYPOXProstat</acronym>
  <official_title>Evaluation of Hypoxia by PET With 18-FluoroMisonidazole During Radiation Therapy of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IASON Gmbh, Feldkirchner strasse 4, 8054 Graz-Seiesberg AUSTRIA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cyclopharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With functional imaging development, it becomes possible to increase radiation dose to
      radioresistant areas (located inside tumor volume) using radiotherapy dose-painting. This
      strategy is particularly suitable for prostate cancer where tumor hypoxia plays a major role
      in the resistance of these tumors to radiation.

      In order to develop intratumoral hypoxia targeting by radiotherapy dose-painting areas, we
      should characterize changes in hypoxia before treatment and during radiotherapy.

        -  If hypoxia does not change during radiotherapy, radiotherapy dose-painting strategy by
           an &quot;integrated&quot; boost is performed.

        -  If hypoxia varied (increasing or incomplete regression), a &quot;final&quot; boost strategy of
           radiotherapy dose-painting(IMRT, stereotactic brachytherapy or high dose rate) after a
           first fractionated IMRT could be considered.

      This study should show that PET imaging with fluoromisonidazole (18F-MISO) is an available
      tool to physicians in assessing tumor hypoxia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize changes in tumor hypoxia (PET with 18F-MISO) during radiation therapy of prostate cancer.</measure>
    <time_frame>3 to 4 weeks after beginning of radiation therapy</time_frame>
    <description>First PET-scan with 18-F-Miso done before radiation Second PET-scan with 18-F-Miso done 3 to 4 weeks after the beginning of radiation therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare hypoxia imaging (PET with 18F-MISO) with anatomical imaging (PET with 18F-choline) to study the feasibility of a tailored treatment.</measure>
    <time_frame>before and 3 to 4 weeks after the begining of radiation therapy</time_frame>
    <description>Images obtained with PET Choline and MRI (anatomical location) will be merge with images obtained by 18F-MISO PET to search hypoxia on these anatomical areas.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>PET imaging, 18 F-miso</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18-F-MISO</intervention_name>
    <description>PET scan with the 18 Fluoro Misonidazole</description>
    <arm_group_label>PET imaging, 18 F-miso</arm_group_label>
    <other_name>18 Fluoro Misonidazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven prostate adenocarcinoma

          -  Absence of metastases (lymph node or bone)

          -  One or more tumor nodules seen on MRI and PET Choline.

          -  Intermediate Risk : Gleason 7 and PSA (prostate specific antigen)&lt;20 ng / ml, T &lt;T2c
             or Gleason 6 and PSA 10-20 ng / ml, T &lt;T2c

          -  No concomitant hormonal treatment. (NB: the introduction of hormone therapy during
             radiotherapy before the second 18F-MISO is a criterion to study exit)

          -  Indication of radiotherapy up to a total dose&gt; 70 Gy and 2 Gy/day fractions

          -  Signed Informed consent

          -  Social Insurance

        Exclusion Criteria:

          -  Age &lt; 18 years old

          -  Patient protected by law
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SUPIOT Stéphane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICO René Gauducheau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Rene Gauducheau</name>
      <address>
        <city>St Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):417-28.</citation>
    <PMID>8892467</PMID>
  </results_reference>
  <results_reference>
    <citation>Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005 Feb;6(2):112-7.</citation>
    <PMID>15683820</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2013</study_first_submitted>
  <study_first_submitted_qc>July 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <last_update_submitted>November 6, 2015</last_update_submitted>
  <last_update_submitted_qc>November 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoxia</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>PET with 18-F-MISO</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misonidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

